Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Long-Term Debt Repayments (2022 - 2025)

Cytek Biosciences' Long-Term Debt Repayments history spans 4 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments rose 2015.11% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $4.7 million, up 751.89%, while the annual FY2025 figure was $4.7 million, 751.89% up from the prior year.
  • Long-Term Debt Repayments reached $2.9 million in Q4 2025 per CTKB's latest filing, up from $145000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $2.9 million in Q4 2025 to a low of $50000.0 in Q4 2022.
  • Average Long-Term Debt Repayments over 4 years is $455153.8, with a median of $140000.0 recorded in 2023.
  • Peak YoY movement for Long-Term Debt Repayments: decreased 4.79% in 2024, then soared 2015.11% in 2025.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $50000.0 in 2022, then soared by 180.0% to $140000.0 in 2023, then decreased by 0.71% to $139000.0 in 2024, then skyrocketed by 2015.11% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Long-Term Debt Repayments are $2.9 million (Q4 2025), $145000.0 (Q3 2025), and $142000.0 (Q2 2025).